Inmunogenicidad en terapia biológica. Implicaciones en Dermatología
Open Access
- 1 July 2013
- journal article
- Published by Elsevier BV in Actas Dermo-Sifiliograficas
- Vol. 104 (6), 471-479
- https://doi.org/10.1016/j.ad.2013.02.005
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximabAnnals Of The Rheumatic Diseases, 2012
- Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasisAnnales de Dermatologie et de Vénéréologie, 2012
- Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendationsJournal of the American Academy of Dermatology, 2010
- Anti‐infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot studyThe Journal of Dermatology, 2010
- Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque PsoriasisArchives of Dermatology, 2010
- Dealing with immunogenicity of biologicals: assessment and clinical relevanceCurrent Opinion in Rheumatology, 2009
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2007
- Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With PsoriasisArchives of Dermatology, 2007
- A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisJournal of the American Academy of Dermatology, 2006
- Immunogenicity of therapeutic proteins: Clinical implications and future prospectsClinical Therapeutics, 2002